TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06482905: Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

Sponsor: Tcelltech Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 52 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$609,552

Rescue Site Savings

+$406,368

Unlock Full NCT06482905 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06482905 Rescue Dossier →